IRAK2 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, ICC, E |
---|---|
Primary Accession | Q8CFA1 |
Other Accession | AAO24761, 37725373 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | Predicted: 68 kDa Observed: 65 kDa |
Application Notes | IRAK2 antibody can be used for detection of IRAK2 by Western blot at 0.5 - 2 µg/mL. Antibody can also be used for immunocytochemistry starting at 1 µg/mL. For immunofluorescence start at 10 µg/mL. |
Gene ID | 108960 |
---|---|
Other Names | IRAK2 Antibody: IRAK-2, AI649099, 6330415L08Rik, Interleukin-1 receptor-associated kinase-like 2, IRAK-2, interleukin-1 receptor-associated kinase 2 |
Target/Specificity | Irak2; At least four isoforms of IRAK2 are known to exist; this antibody will detect all four isoforms. Anti-IRAK2 has no cross response to IRAK. |
Reconstitution & Storage | IRAK2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | IRAK2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Irak2 |
---|---|
Function | Binds to the IL-1 type I receptor following IL-1 engagement, triggering intracellular signaling cascades leading to transcriptional up-regulation and mRNA stabilization. |
Tissue Location | Ubiquitously expressed, with a higher expression observed in brain, spleen and liver. Isoform 1 and isoform 2 are considered agonist and isoform 3 and isoform 4 are considered antagonist |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IRAK2 Antibody: The pro-inflammatory cytokine IL-1 induces cellular response through two subunits of its receptor, IL-1 receptor I (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP). IL-1 receptor-associated kinase (IRAK) mediates activation of NF-κB, which is a pivotal transcription factor mediating inflammatory and immune response. A novel member in the IRAK/Pelle family has been identified and designated IRAK2. Both IRAK and IRAK2 recruit to the subunits of the IL-1R complex after IL-1 binding and lead to NF-κB activation. IRAKs also associate with Toll like receptor (TLR) and the dominant negative mutants of IRAKs inhibit LPS-induced NF-kB activation. Members in IRAK/Pelle family play a central role in IL-1R and TLR mediated inflammatory response. Unlike human IRAK2, murine IRAK2 exists as four alternately spliced isoforms (IRAK2a-d), with two isoforms (IRAK2c and d) acting in an inhibitory fashion. IRAK2 is expressed in a variety of tissues.
References
Muzio M, Ni J, Feng P, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278:1612-5.
Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem. 1999; 274:7611-4.
Yang RB, Mark MR, Gurney AL, et al. Signaling events induced by lipopolysaccharide-activated toll-like receptor 2. J. Immunol. 1999; 163:639-43.
Hardy MP and O’Neill LAJ. The murine IRAK2 gene encodes four alternately spliced isoforms, two of which are inhibitory. J. Biol. Chem. 2004; 279:27699-708.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.